|
Name |
Zelkovamycin C
|
| Molecular Formula | C36H45N9O10S | |
| IUPAC Name* |
(4S,7S,13R,16Z,22R)-7-acetyl-13-ethyl-16-ethylidene-4-[(5-hydroxy-4-methoxy-1H-indol-3-yl)methyl]-7,18,22-trimethyl-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone
|
|
| SMILES |
CC[C@@H]1C(=O)N/C(=C\C)/C(=O)N(CC(=O)N[C@@H](C2=NC(=CS2)C(=O)N[C@H](C(=O)N[C@@](C(=O)NCC(=O)N1)(C)C(=O)C)CC3=CNC4=C3C(=C(C=C4)O)OC)C)C
|
|
| InChI |
InChI=1S/C36H45N9O10S/c1-8-20-30(50)41-21(9-2)34(53)45(6)15-27(49)39-17(3)33-43-24(16-56-33)31(51)42-23(12-19-13-37-22-10-11-25(47)29(55-7)28(19)22)32(52)44-36(5,18(4)46)35(54)38-14-26(48)40-20/h9-11,13,16-17,20,23,37,47H,8,12,14-15H2,1-7H3,(H,38,54)(H,39,49)(H,40,48)(H,41,50)(H,42,51)(H,44,52)/b21-9-/t17-,20-,23+,36+/m1/s1
|
|
| InChIKey |
OORNONOEAPJBHY-IXVWJLNKSA-N
|
|
| Synonyms |
Zelkovamycin C
|
|
| CAS | NA | |
| PubChem CID | 156582955 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 795.9 | ALogp: | 0.5 |
| HBD: | 8 | HBA: | 12 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 298.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 56 | QED Weighted: | 0.128 |
| Caco-2 Permeability: | -5.921 | MDCK Permeability: | 0.00000367 |
| Pgp-inhibitor: | 0.062 | Pgp-substrate: | 1 |
| Human Intestinal Absorption (HIA): | 0.737 | 20% Bioavailability (F20%): | 0.99 |
| 30% Bioavailability (F30%): | 0.993 |
| Blood-Brain-Barrier Penetration (BBB): | 0.099 | Plasma Protein Binding (PPB): | 77.44% |
| Volume Distribution (VD): | 0.299 | Fu: | 36.94% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.109 |
| CYP2C19-inhibitor: | 0.095 | CYP2C19-substrate: | 0.038 |
| CYP2C9-inhibitor: | 0.233 | CYP2C9-substrate: | 0.568 |
| CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.1 |
| CYP3A4-inhibitor: | 0.121 | CYP3A4-substrate: | 0.073 |
| Clearance (CL): | 2.447 | Half-life (T1/2): | 0.83 |
| hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.504 |
| Drug-inuced Liver Injury (DILI): | 0.824 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.667 |
| Skin Sensitization: | 0.149 | Carcinogencity: | 0.018 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.003 |
| Respiratory Toxicity: | 0.165 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002016 | ![]() |
0.819 | D09ZIO | ![]() |
0.285 | ||
| ENC004435 | ![]() |
0.815 | D0X9PF | ![]() |
0.246 | ||
| ENC004434 | ![]() |
0.801 | D0M2YE | ![]() |
0.232 | ||
| ENC004433 | ![]() |
0.704 | D0L7LC | ![]() |
0.232 | ||
| ENC005139 | ![]() |
0.343 | D07DSQ | ![]() |
0.227 | ||
| ENC005276 | ![]() |
0.303 | D0E2OU | ![]() |
0.223 | ||
| ENC005343 | ![]() |
0.294 | D02XIY | ![]() |
0.219 | ||
| ENC002515 | ![]() |
0.282 | D0D8XY | ![]() |
0.216 | ||
| ENC005563 | ![]() |
0.275 | D02SBQ | ![]() |
0.215 | ||
| ENC002514 | ![]() |
0.275 | D07XGH | ![]() |
0.214 | ||